openPR Logo
Press release

Trial Attorney Says Merck is 'Step Closer to Accountability' as VIOXX Trial Continues

03-07-2007 07:39 PM CET | Politics, Law & Society

Press release from: The Lanier Law Firm

Mark Lanier, The Lanier Law Firm

Mark Lanier, The Lanier Law Firm

Attorney Mark Lanier: 'Merck Can't Turn a Loss Into a Win Just By Saying It's So'

ATLANTIC CITY, N.J., March 7 /PRNewswire/ -- A jury on Friday in New Jersey Superior Court imposed a serious and strong verdict against Merck & Co., finding that the manufacturer of VIOXX(R) withheld information and made misrepresentations to doctors and to the public about the heart attack risks associated with the drug.

The jury unanimously confirmed four counts of fraud in the marketing of VIOXX(R) making Merck liable for millions of dollars in damages, attorney fees and expenses. Also, the jury unanimously found that Merck failed to adequately warn patient Mike Humeston about the dangers posed by Vioxx. In doing so, jurors reversed a 2005 finding on behalf of Merck against the Humeston family.

Mark Lanier, lead attorney for the victims of VIOXX(R) says, "Since the verdict, spinmeisters on behalf of Merck have attempted to characterize this significant defeat as somehow a victory." Merck received one positive finding out of six from jurors who found that Merck provided adequate warning before the fatal heart attack of Brian Hermans. According to Lanier, "The practical impact of that finding is minimal. It means that Brian's family can't pursue damages that would have been capped at $350,000. While that represents a substantial amount of money, it is
dwarfed by the financial liability Merck faces for defrauding the public and the medical community."

In phase two of the current trial, jurors will determine whether VIOXX(R) was a primary cause of Mr. Humeston's heart attack. Jurors will also determine damages for both plaintiffs under New Jersey's consumer fraud laws.

Merck is expected to appeal the verdicts in both the Hermans and Humeston cases, rather than pay millions of dollars in damages and fees. Lanier and The Lanier Law Firm have faced Merck on behalf of five separate
plaintiffs. Merck is appealing the result in each case.

VIOXX(R) was approved by the Food and Drug Administration in May 1999 for the relief of osteoarthritis and menstrual pain, and later for treatment of the signs and symptoms of rheumatoid arthritis. Merck pulled
the drug from pharmacy shelves in September 2004 after a study linked it to an increased risk of heart attacks. Merck, the No. 4 drug maker in the country, now faces nearly 27,000 suits over the drug.

Mr. Lanier won the first-ever VIOXX(R) trial in the summer of 2005, when an Angleton, Texas, jury awarded his client $253.5 million. In that case, jurors found Merck liable in the 2001 death of Robert Ernst, a physically fit triathlete who died after taking the drug for eight months.

With offices in Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and often untraditional solutions. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, business fraud, serious personal injuries, product liability, and toxic exposure. For more information, visit

The Lanier Law Firm

Houston Law Office
6810 FM 1960 West
Houston, Texas 77069
(713) 659-5200
(713) 659-2204 – Fax

New York Law Office
Lanier Law Firm, PLLC
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
(212) 421-2800
(212) 421-2878 – Fax

Press contact:
Mike Androvett

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Trial Attorney Says Merck is 'Step Closer to Accountability' as VIOXX Trial Continues here

News-ID: 16676 • Views:

More Releases for Merck

Recombinant Human Interferon Market to Witness Huge Growth by Key Players: Roche …
The Recombinant Human Interferon report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Recombinant Human Interferon research report recognizes and
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI. The Nanobodies market report analyse the manufacturing cost of the
How Epigenomics Market Will Dominate In Coming Years? Key Players: Thermo Fisher …
Fortune Business Insights foresees the pharmaceutical segment to dominate the global epigenomics market on account of the increasing prevalence of chronic diseases such as cancer. According to the World Health Organization (WHO), by the end of 2025, the number of cancer patients will reach 21,471,996. Sample PDF Brochure The increasing prevalence of chronic diseases such as cancer is helping the global epigenomics market to emerge with remarkable market figures, finds
Global Immune Checkpoint Inhibitors Market 2026 : Bristol-Myers Squibb, AstraZen …
Researchmoz added latest report "Global Market Study on Immune Checkpoint Inhibitors: Programmed Death Protein 1 (PD-1) Drug Class to Dominate in Terms of Value Through 2026". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Persistence Market Research (PMR) offers an 8-year forecast on the global immune checkpoint inhibitors market. The primary objective of the report is to offer
Pharmaceuticals Excipients Market 2018 Global Analysis By Key Players – Ashlan …
Summary adds “Pharmaceuticals Excipients Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database. This report provides in depth study of “Pharmaceuticals Excipients Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Pharmaceuticals Excipients Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as
Pneumonia Vaccine Market- GlaxoSmithKline, Pfizer, Merck
Global Pneumonia Vaccine Market Size, Status and Forecast 2022 provides Market information about Manufacturers, Countries, Type and Application.This Industry report also states Company Profile, sales, Pneumonia Vaccine Market revenue and price, market share, market growth and gross margin by regions. Top Manufacturers/Key Players:- GlaxoSmithKline Pfizer Merck Enquiry for buying report @ The Global Pneumonia Vaccine report gives a thorough situation of the present and gauge Pneumonia Vaccine showcase procedures, improvement methodologies and development openings.